| 1 | complete | 16,253 |
| 2 | near-complete | 40 |
| 3 | corticosteroid-free | 28 |
| 4 | canine-guided | 6 |
| 5 | carinal | 5 |
| 6 | polyantigenic | 5 |
| 7 | clinical-only | 4 |
| 8 | monofollicular | 4 |
| 9 | partial-complete | 4 |
| 10 | springtime | 4 |
| 11 | unmaintained | 4 |
| 12 | ball-attachment | 3 |
| 13 | clinical/endoscopic | 3 |
| 14 | endoscopically-confirmed | 3 |
| 15 | full-matrix | 3 |
| 16 | incomplete/no | 3 |
| 17 | lidocaine-induced | 3 |
| 18 | post-cryopreservation | 3 |
| 19 | rhomboidal | 3 |
| 20 | three-humor | 3 |
| 21 | 9x | 2 |
| 22 | ab-mediated | 2 |
| 23 | biologic-free | 2 |
| 24 | complete/incomplete | 2 |
| 25 | das28-defined | 2 |
| 26 | gastroscopically-determined | 2 |
| 27 | molecular/immunological | 2 |
| 28 | nonadverse | 2 |
| 29 | postoperativ | 2 |
| 30 | shaving-induced | 2 |
| 31 | ymrs/hdrs | 2 |
| 32 | 'microbiological | 1 |
| 33 | 0.5-mb | 1 |
| 34 | 1.9-å | 1 |
| 35 | 1.95å | 1 |
| 36 | 2.0-å | 1 |
| 37 | 2.25å | 1 |
| 38 | 3-hmg-coenzym | 1 |
| 39 | 3-hydroxy-3-methylglutaryl-co-enzyme | 1 |
| 40 | abdei-mogib | 1 |
| 41 | anti-hpv6/11/16/18 | 1 |
| 42 | apstein | 1 |
| 43 | asas20/asas40 | 1 |
| 44 | billewitz | 1 |
| 45 | chemotherapy-maintained | 1 |
| 46 | class-for | 1 |
| 47 | clinical-biochemical | 1 |
| 48 | complete/near-to-complete | 1 |
| 49 | das28/crp-defined | 1 |
| 50 | delay-matched | 1 |
| 51 | employment-providing | 1 |
| 52 | frattini | 1 |
| 53 | hypothalamo-hypophyseal | 1 |
| 54 | inadequate/adequate | 1 |
| 55 | ivig-induced | 1 |
| 56 | jarzembska | 1 |
| 57 | magneto/electrophysiological | 1 |
| 58 | mantained | 1 |
| 59 | mesoretcal | 1 |
| 60 | nikolsky | 1 |
| 61 | partia1 | 1 |
| 62 | participatively | 1 |
| 63 | postneoplasm | 1 |
| 64 | prather | 1 |
| 65 | psa-defined | 1 |
| 66 | salafia | 1 |
| 67 | say- | 1 |
| 68 | seiler | 1 |
| 69 | varicosis-related | 1 |
| 70 | vercillini | 1 |
| 71 | verhaak | 1 |
| 72 | very-bad-risk | 1 |
| 73 | vitti | 1 |
| 1 | 'microbiological | 1 |
| 2 | 0.5-mb | 1 |
| 3 | 1.9-å | 1 |
| 4 | 1.95å | 1 |
| 5 | 2.0-å | 1 |
| 6 | 2.25å | 1 |
| 7 | 3-hmg-coenzym | 1 |
| 8 | 3-hydroxy-3-methylglutaryl-co-enzyme | 1 |
| 9 | 9x | 2 |
| 10 | ab-mediated | 2 |
| 11 | abdei-mogib | 1 |
| 12 | anti-hpv6/11/16/18 | 1 |
| 13 | apstein | 1 |
| 14 | asas20/asas40 | 1 |
| 15 | ball-attachment | 3 |
| 16 | billewitz | 1 |
| 17 | biologic-free | 2 |
| 18 | canine-guided | 6 |
| 19 | carinal | 5 |
| 20 | chemotherapy-maintained | 1 |
| 21 | class-for | 1 |
| 22 | clinical-biochemical | 1 |
| 23 | clinical-only | 4 |
| 24 | clinical/endoscopic | 3 |
| 25 | complete | 16,253 |
| 26 | complete/incomplete | 2 |
| 27 | complete/near-to-complete | 1 |
| 28 | corticosteroid-free | 28 |
| 29 | das28-defined | 2 |
| 30 | das28/crp-defined | 1 |
| 31 | delay-matched | 1 |
| 32 | employment-providing | 1 |
| 33 | endoscopically-confirmed | 3 |
| 34 | frattini | 1 |
| 35 | full-matrix | 3 |
| 36 | gastroscopically-determined | 2 |
| 37 | hypothalamo-hypophyseal | 1 |
| 38 | inadequate/adequate | 1 |
| 39 | incomplete/no | 3 |
| 40 | ivig-induced | 1 |
| 41 | jarzembska | 1 |
| 42 | lidocaine-induced | 3 |
| 43 | magneto/electrophysiological | 1 |
| 44 | mantained | 1 |
| 45 | mesoretcal | 1 |
| 46 | molecular/immunological | 2 |
| 47 | monofollicular | 4 |
| 48 | near-complete | 40 |
| 49 | nikolsky | 1 |
| 50 | nonadverse | 2 |
| 51 | partia1 | 1 |
| 52 | partial-complete | 4 |
| 53 | participatively | 1 |
| 54 | polyantigenic | 5 |
| 55 | post-cryopreservation | 3 |
| 56 | postneoplasm | 1 |
| 57 | postoperativ | 2 |
| 58 | prather | 1 |
| 59 | psa-defined | 1 |
| 60 | rhomboidal | 3 |
| 61 | salafia | 1 |
| 62 | say- | 1 |
| 63 | seiler | 1 |
| 64 | shaving-induced | 2 |
| 65 | springtime | 4 |
| 66 | three-humor | 3 |
| 67 | unmaintained | 4 |
| 68 | varicosis-related | 1 |
| 69 | vercillini | 1 |
| 70 | verhaak | 1 |
| 71 | very-bad-risk | 1 |
| 72 | vitti | 1 |
| 73 | ymrs/hdrs | 2 |
| 1 | say- | 1 |
| 2 | asas20/asas40 | 1 |
| 3 | partia1 | 1 |
| 4 | anti-hpv6/11/16/18 | 1 |
| 5 | salafia | 1 |
| 6 | jarzembska | 1 |
| 7 | abdei-mogib | 1 |
| 8 | 0.5-mb | 1 |
| 9 | polyantigenic | 5 |
| 10 | clinical/endoscopic | 3 |
| 11 | lidocaine-induced | 3 |
| 12 | ivig-induced | 1 |
| 13 | shaving-induced | 2 |
| 14 | canine-guided | 6 |
| 15 | delay-matched | 1 |
| 16 | endoscopically-confirmed | 3 |
| 17 | mantained | 1 |
| 18 | chemotherapy-maintained | 1 |
| 19 | unmaintained | 4 |
| 20 | das28-defined | 2 |
| 21 | psa-defined | 1 |
| 22 | das28/crp-defined | 1 |
| 23 | gastroscopically-determined | 2 |
| 24 | ab-mediated | 2 |
| 25 | varicosis-related | 1 |
| 26 | biologic-free | 2 |
| 27 | corticosteroid-free | 28 |
| 28 | springtime | 4 |
| 29 | 3-hydroxy-3-methylglutaryl-co-enzyme | 1 |
| 30 | nonadverse | 2 |
| 31 | inadequate/adequate | 1 |
| 32 | complete | 16,253 |
| 33 | partial-complete | 4 |
| 34 | complete/near-to-complete | 1 |
| 35 | near-complete | 40 |
| 36 | complete/incomplete | 2 |
| 37 | employment-providing | 1 |
| 38 | vercillini | 1 |
| 39 | frattini | 1 |
| 40 | vitti | 1 |
| 41 | verhaak | 1 |
| 42 | very-bad-risk | 1 |
| 43 | 'microbiological | 1 |
| 44 | magneto/electrophysiological | 1 |
| 45 | molecular/immunological | 2 |
| 46 | clinical-biochemical | 1 |
| 47 | mesoretcal | 1 |
| 48 | rhomboidal | 3 |
| 49 | hypothalamo-hypophyseal | 1 |
| 50 | carinal | 5 |
| 51 | postneoplasm | 1 |
| 52 | 3-hmg-coenzym | 1 |
| 53 | apstein | 1 |
| 54 | post-cryopreservation | 3 |
| 55 | incomplete/no | 3 |
| 56 | monofollicular | 4 |
| 57 | prather | 1 |
| 58 | seiler | 1 |
| 59 | class-for | 1 |
| 60 | three-humor | 3 |
| 61 | ymrs/hdrs | 2 |
| 62 | ball-attachment | 3 |
| 63 | postoperativ | 2 |
| 64 | 9x | 2 |
| 65 | full-matrix | 3 |
| 66 | nikolsky | 1 |
| 67 | participatively | 1 |
| 68 | clinical-only | 4 |
| 69 | billewitz | 1 |
| 70 | 2.0-å | 1 |
| 71 | 1.9-å | 1 |
| 72 | 2.25å | 1 |
| 73 | 1.95å | 1 |